Inhibrx Inc
Prices are adjusted according to historical splits.
Vitals
- Today's Low:
- $20.31
- Today's High:
- $21.4
- Open Price:
- $20.31
- 52W Low:
- $12.6
- 52W High:
- $34.72
- Prev. Close:
- $20.44
- Volume:
- 539865
Company Statistics
- Market Cap.:
- $984.72 million
- Book Value:
- -0.568
- Revenue TTM:
- $599000
- Operating Margin TTM:
- -25143.24%
- Gross Profit TTM:
- $-107994000
- Profit Margin:
- 0%
- Return on Assets TTM:
- -46.33%
- Return on Equity TTM:
- -766.84%
Company Profile
Inhibrx Inc had its IPO on 2020-08-19 under the ticker symbol INBX.
The company operates in the Healthcare sector and Biotechnology industry. Inhibrx Inc has a staff strength of 132 employees.
Stock update
Shares of Inhibrx Inc opened at $20.31 at the start of the last trading session i.e. 2023-09-12.
The stocks traded within a range of $20.31 - $21.4, and closed at $20.44.
This is a 0% increase from the previous day's closing price.
A total volume of 539,865 shares were traded at the close of the day’s session.
In the last one week, shares of Inhibrx Inc have slipped by -9.36%.
Inhibrx Inc's Key Ratios
Inhibrx Inc has a market cap of $984.72 million, indicating a price to book ratio of 35.0448 and a price to sales ratio of 255.6159.
In the last 12-months Inhibrx Inc’s revenue was $599000 with a gross profit of $-107994000 and an EBITDA of $-149408000. The EBITDA ratio measures Inhibrx Inc's overall financial performance and is widely used to measure its profitability.
In the trailing 12-month period, Inhibrx Inc’s operating margin was -25143.24% while its return on assets stood at -46.33% with a return of equity of -766.84%.
In Q2, Inhibrx Inc’s quarterly earnings growth was a positive 0% while revenue growth was a negative 95.8%.
Inhibrx Inc’s PE and PEG Ratio
- Forward PE
- 0
- Trailing PE
- 0
- PEG
Its diluted EPS in the last 12-months stands at $-4.33 per share while it has a forward price to earnings multiple of 0 and a PEG multiple of . A low price to earnings ratio can mean the stock is attractively valued while a high ratio suggests the stock may be overvalued.
The PEG on the other hand provides a broader view compared to the P/E ratio and gives greater insight into Inhibrx Inc’s profitability.
Inhibrx Inc stock is trading at a EV to sales ratio of 276.6873 and a EV to EBITDA ratio of -11.7386. Its price to sales ratio in the trailing 12-months stood at 255.6159.
Inhibrx Inc stock pays annual dividends of $0 per share, indicating a yield of 0% and a payout ratio of 0%.
Balance sheet and cash flow metrics
- Total Assets
- $213.17 million
- Total Liabilities
- $31.33 million
- Operating Cash Flow
- $-317000.00
- Capital Expenditure
- $317000
- Dividend Payout Ratio
- 0%
Inhibrx Inc ended 2024 with $213.17 million in total assets and $0 in total liabilities. Its intangible assets were valued at $213.17 million while shareholder equity stood at $-24812000.00.
Inhibrx Inc ended 2024 with $0 in deferred long-term liabilities, $31.33 million in other current liabilities, 4000.00 in common stock, $-468341000.00 in retained earnings and $0 in goodwill. Its cash balance stood at $192.49 million and cash and short-term investments were $192.49 million. The company’s total short-term debt was $1,959,000 while long-term debt stood at $204.48 million.
Inhibrx Inc’s total current assets stands at $203.32 million while long-term investments were $0 and short-term investments were $0. Its net receivables were $327000.00 compared to accounts payable of $9.70 million and inventory worth $10.18 million.
In 2024, Inhibrx Inc's operating cash flow was $-317000.00 while its capital expenditure stood at $317000.
Comparatively, Inhibrx Inc paid $0 in dividends in 2024.
Other key metrics
- Current Trading Price
- $20.44
- 52-Week High
- $34.72
- 52-Week Low
- $12.6
- Analyst Target Price
- $49
Inhibrx Inc stock is currently trading at $20.44 per share. It touched a 52-week high of $34.72 and a 52-week low of $34.72. Analysts tracking the stock have a 12-month average target price of $49.
Its 50-day moving average was $21.22 and 200-day moving average was $23.35 The short ratio stood at 15.14 indicating a short percent outstanding of 0%.
Around 2161.1% of the company’s stock are held by insiders while 8530.5% are held by institutions.
Frequently Asked Questions About Inhibrx Inc
Similar Industry Stocks (Biotechnology)
Most Active
Top Gainers
Top Losers
About
Inhibrx, Inc., a clinical-stage biopharmaceutical company, focuses on developing a pipeline of novel biologic therapeutic candidates. The company’s therapeutic candidates include INBRX-109, a tetravalent agonist of death receptor 5, which is in Phase 2 clinical trials to treat cancers, such as chondrosarcoma, mesothelioma, and pancreatic adenocarcinoma; INBRX-105, a tetravalent conditional agonist of programmed death-ligand 1 and a conditional agonist of 4-1BB that is in Phase 1 clinical trials to treat patients with locally advanced or metastatic solid tumors; and INBRX-101, an alpha-1 antitrypsin (AAT)-Fc fusion protein therapeutic candidate, which is in Phase 1 clinical trials for use in the treatment of patients with AAT deficiency. It also develops INBRX-106, a hexavalent agonist of OX40 for a range of oncology indications. The company has collaboration with 2seventy bio, Inc., Bristol-Myers Squibb Company, and Chiesi Farmaceutici S.p.A. The company was founded in 2010 and is headquartered in La Jolla, California.